Phexxi as a Contraceptive; Commercial Strategies

According to our market research since Phexxi's commercial launch, HCPs indicate they would recommend Phexxi to approximately:

•47% of patients experiencing side effects from current contraception; •37% of patients using non-hormonal prescription contraception; •36% of patients seeking pregnancy prevention; and •19% of patients using hormonal prescription contraception.

Approved claims for Phexxi have increased throughout 2022, and currently 70% of Phexxi claims are being approved, up from a low of 55%.

We continue working to increase the number of lives covered and to gain a preferred formulary position for Phexxi. Effective July 1, 2022, Phexxi will have coverage for approximately 60% of U.S. commercial lives. This includes:

Phexxi for the Prevention of Chlamydia and Gonorrhea

Additionally, the FDA has designated EVO100 (the investigational name for Phexxi) as a Qualified Infectious Disease Product (QIDP) for the prevention of both chlamydia and gonorrhea in women, which provides several important potential advantages, including, but not limited to, longer market exclusivity.

Multipurpose Prevention Technology Vaginal Gel for HIV Prevention

Inventory costs include all purchased materials, direct labor and manufacturing overhead.

We expense internal and third-party research and development expenses as incurred. The following table summarizes research and development expenses by product candidate (in thousands):

Allocated third-party development expenses: EVO100 for prevention of chlamydia/gonorrhea- Phase 3 (EVOGUARD)

$ 5,926 $ 13,742 $ 10,188 Total allocated third-party development expenses

Total unallocated internal research and development expenses

The costs of clinical trials may vary significantly over the life of a program owing to the following:

The increase in cost of goods sold was primarily due to the increase in sales in the current period versus the same period in the prior year.

4 - Debt and a $8.9 million gain from the change in fair value of the Baker Notes as a result of mark-to-market adjustments during the quarter.

The increase in cost of goods sold was primarily due to the increase in sales in the current period versus the same period in the prior year.

Total other income, net, for the six months ended June 30, 2021, primarily included $2.3 million in interest expense related to the Baker Notes and the Adjuvant Notes as described in Note

© Edgar Online, source Glimpses